Peptide antagonists at glutamate and NMDA receptors

Abstract

Peptide antagonists of glutamate receptors and a subtype of glutamate receptors [NMDA(N-methyl-D-aspartate)receptors] influence glutamate receptor- and NMDA receptor-controlled cells, such as neurons or glial cells in the central nervous system; and can be used in the treatment of acute or chronic disorders of the central nervous system and the treatment of hypoxic, ischemic, and metabolic brain disorders.

1 . Use of peptide antagonists at glutamate receptors for the manufacture of a medicament to influence the glutamate-receptor-controlled cells.  
     
     
         2 . Use of peptide antagonists at NMDA receptors for the manufacture of a medicament to influence the NMDA-receptor-controlled cells.  
     
     
         3 . Use according to  claim 2  in which the medicament prevents NMDA-receptor-mediated excitatory effects such as release of neurotransmitter or peptide as well as toxic effects resulting in cell injury or death.  
     
     
         4 . Use according to any of  claims 1  to  3  in which the cells are neurons or glial cells in the central nervous system.  
     
     
         5 . Use according to any of  claims 1  to  4  in which the medicament comprises glutamic acid-terminating peptides.  
     
     
         6 . Use according to any of  claims 1  to  5  in which the antagonist is chosen among (1-5)GnRH, (1-3)IGF-I, (1-37)GRF and C-peptide of insulin.  
     
     
         7 . Use according to any of  claims 1  to  6  in which the medicament influence GnRH secretion.  
     
     
         8 . Use according to any of  claims 1  to  7  for the treatment of acute or chronic disorders of the central nervous system.  
     
     
         9 . Use according to any of  claims 1  to  7  for the treatment of hypoxic, ischemic and metabolic brain disorders such as stroke and hypoglycaemia, traumatic, radiation-induced or inflammatory injuries to the brain and chronic degenerative states.  
     
     
         10 . Use according to any of  claims 1  to  9  for the treatment of children during the perinatal period and infancy.  
     
     
         11 . Use according to any of  claims 1  to  10  in which the medicament comprises (1-3) IGF-I.  
     
     
         12 . Use according to any of  claims 1  to  11  in which the medicament is administered systemically.  
     
     
         13 . Use according to any of  claims 1  to  11  in which the medicament is administered locally.  
     
     
         14 . Method for influence on glutamate-receptor-controlled cells by administration of peptide antagonists at glutamate receptors.  
     
     
         15 . Method for influence on NMDA-receptor-controlled cells by administration of peptide antagonists at NMDA receptors.  
     
     
         16 . Method according to  claim 15  for preventing NMDA-receptor mediated excitatory effects such as release of neurotransmitter or peptide as well as toxic effects resulting in cell injury or death.  
     
     
         17 . Method according to any of  claims 14  to  16  for influence on the function of neurons or glial cells in the central nervous system.  
     
     
         18 . Method according to any of  claims 14  to  17  in which the antagonists at NMDA receptors comprises glutamic acid-terminating peptides.  
     
     
         19 . Method according to any of  claim 14  to  18  in which the antagonist is chosen among (1-5)GnRH, (1-3)IGF-I, (1-37)GRF and C-peptide of insulin.  
     
     
         20 . Method according to any of  claim 14  to  19  for influencing the GnRH secretion.  
     
     
         21 . Method according to any of  claims 14  to  120  for the treatment of acute or chronic disorders of the central nervous system.  
     
     
         22 . Method according to any of  claims 14  to  20  for the treatment of hypoxic, ischemic and metabolic brain disorders such as stroke and hypoglycaemia, traumatic, radiation-induced or inflammatory injuries to the brain and chronic degenerative states.  
     
     
         23 . Method according to any of  claims 14  to  21  for the treatment of children during the perinatal period and infancy.  
     
     
         24 . Method according to any of  claims 14  to  22  in which a medicament is administered which comprises (1-3) IGF-I.  
     
     
         25 . Method according to any of  claims 14  to  23  in which a medicament is administered systemically.  
     
     
         26 . Method according to any of  claims 14  to  23  in which a medicament is administered locally.